All In Biotech

Drug Trial Radar · NCT04250922

LAM561 With RT and TMZ for Adults With Glioblastoma

A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

144

Actual

Start

Dec 1, 2019

Primary completion

Jan 15, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Laminar PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Laboratory Corporation of America; Northern Institute for Cancer Research, Newcastle; Theradis pharma; LIPODOM THERAPEUTICS
First posted
Jan 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.

Conditions

  • Primary Glioblastoma
  • Glioblastoma Multiforme

Interventions

  • LAM561Drug

    Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase. Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment.

  • TMZDrug

    TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days. During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles.

  • RTRadiation

    During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of LAM561 in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ.Time frame: Assessed after observing at least 66 PFS events
  2. To evaluate the efficacy of LAM561 in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ.Time frame: Assessed after observing at least 90 OS events

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • Institut Cancerologie de L'Ouest (ICO)

    Angers, France

  • Centre Eugène Marquis (CEM)

    Rennes, France

  • Gustave Roussy University Hospital

    Rennes, France

  • Institut universitaire du cancer

    Toulouse, France

  • Reaserch Fund of the Hadassah Medical Organization

    Jerusalem, Israel

  • Istituto Nazionale Neurologico Carlo Besta

    Milan, Italy

  • Istituto Nazionale Tumori "Regina Elena"

    Roma, Italy

  • University of Turin

    Turin, Italy

  • Istituto Oncologico Veneto IRCCS

    Padova, Veneto, Italy

  • Hospital del Mar

    Barcelona, Spain

  • Hospital Universitario 12 De Octubre

    Madrid, Spain

  • Hospital Parc Tauli

    Sabadell, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, Andalusia, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Andalusia, Spain

  • Hospital Clinic

    Barcelona, Barcelona, Spain

  • Hospital Vall d'Hebron

    Barcelona, Barcelona, Spain

  • Hospital Clínico San Carlos

    Madrid, Madrid, Spain

  • Hospital Universitari i Politécnic La Fe.

    Valencia, Valencia, Spain

  • University Hospitals Birmingham NHS Foundation Trust - New Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Cambridge university hospital

    Cambridge, United Kingdom

  • The Royal Marsden Hospital

    London, United Kingdom

  • Freeman Hospital's Northern Centre of Cancer Care

    Newcastle, Newcastle Upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.